South Korea · Delayed Price · Currency is KRW SyntekaBio Statistics
Total Valuation
SyntekaBio has a market cap or net worth of KRW 44.20 billion. The enterprise value is 38.60 billion.
| Market Cap | 44.20B |
| Enterprise Value | 38.60B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SyntekaBio has 24.26 million shares outstanding. The number of shares has increased by 16.88% in one year.
| Current Share Class | 24.26M |
| Shares Outstanding | 24.26M |
| Shares Change (YoY) | +16.88% |
| Shares Change (QoQ) | +48.67% |
| Owned by Insiders (%) | 15.69% |
| Owned by Institutions (%) | n/a |
| Float | 20.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.82 |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.16 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.74 |
| Interest Coverage | -4.19 |
Financial Efficiency
Return on equity (ROE) is -58.95% and return on invested capital (ROIC) is -19.65%.
| Return on Equity (ROE) | -58.95% |
| Return on Assets (ROA) | -16.34% |
| Return on Invested Capital (ROIC) | -19.65% |
| Return on Capital Employed (ROCE) | -36.70% |
| Weighted Average Cost of Capital (WACC) | 9.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.96% in the last 52 weeks. The beta is 0.35, so SyntekaBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -74.96% |
| 50-Day Moving Average | 2,656.26 |
| 200-Day Moving Average | 3,779.89 |
| Relative Strength Index (RSI) | 32.36 |
| Average Volume (20 Days) | 168,325 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SyntekaBio had revenue of KRW 2.98 billion and -13.58 billion in losses. Loss per share was -761.51.
| Revenue | 2.98B |
| Gross Profit | 2.98B |
| Operating Income | -11.31B |
| Pretax Income | -13.58B |
| Net Income | -13.58B |
| EBITDA | -9.33B |
| EBIT | -11.31B |
| Loss Per Share | -761.51 |
Balance Sheet
The company has 13.40 billion in cash and 7.80 billion in debt, with a net cash position of 5.60 billion or 230.87 per share.
| Cash & Cash Equivalents | 13.40B |
| Total Debt | 7.80B |
| Net Cash | 5.60B |
| Net Cash Per Share | 230.87 |
| Equity (Book Value) | 28.34B |
| Book Value Per Share | 1,168.07 |
| Working Capital | 2.03B |
Cash Flow
In the last 12 months, operating cash flow was -10.37 billion and capital expenditures -176.08 million, giving a free cash flow of -10.54 billion.
| Operating Cash Flow | -10.37B |
| Capital Expenditures | -176.08M |
| Depreciation & Amortization | 1.99B |
| Net Borrowing | -11.43B |
| Free Cash Flow | -10.54B |
| FCF Per Share | -434.58 |
Margins
| Gross Margin | 99.88% |
| Operating Margin | -379.27% |
| Pretax Margin | -455.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SyntekaBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.88% |
| Shareholder Yield | -16.88% |
| Earnings Yield | -30.72% |
| FCF Yield | -23.85% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SyntekaBio has an Altman Z-Score of -0.37 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.37 |
| Piotroski F-Score | 4 |